Combination Therapy With Casirivimab/Imdevimab and Remdesivir for Protracted SARS-CoV-2 Infection in B-cell-Depleted Patients. (26th May 2022)

• Record Type: Journal Article
• Authors: Dioverti, M Veronica; Gaston, David C; Morris, C Paul; Huff, Carol Ann; Jain, Tania; Jones, Richard; Anders, Viki; Lederman, Howard; Saunders, Jacqueline; Mostafa, Heba H; Avery, Robin K
• Is Part Of: Open forum infectious diseases. Volume 9:Number 6(2022)
• Publication Date: 2022-05-26
• Subjects: B-cell-depleted -- monoclonal antibodies -- prolonged SARS-CoV-2; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofac064
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Profoundly B-cell-depleted patients can have prolonged severe acute respiratory syndrome coronavirus 2 infections with evidence of active viral replication, due to inability to mount an adequate humoral response to clear the virus. We present 3 B-cell-depleted patients with prolonged coronavirus disease 2019 infection who were successfully treated with a combination of casirivimab/imdevimab and remdesivir.